Matthew F. Buas Matthew Buas, PhD

Matthew F. Buas


Special Interests:

Cancer precursor lesions Genetic susceptibility Risk assessment Liquid biopsy Omics-based classifiers

About Matthew F. Buas


Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Assistant Member
  • Department of Cancer Prevention and Control
State University of New York at Buffalo
  • Research Assistant Professor
  • Department of Cancer Pathology and Prevention


Education and Training:

  • PhD - Cell & Molecular Biology, University of Pennsylvania, Philadelphia, PA
  • MS - Epidemiology, University of Washington, Seattle, WA


  • Post-doctoral Fellowship - Fred Hutchinson Cancer Research Center, Seattle, WA

Professional Memberships:

  • American Association for Cancer Research (AACR)
  • Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON)


Research Overview:

Dr. Buas’ primary research focus is the molecular/genetic epidemiology of esophageal adenocarcinoma (EA), and the development of novel approaches for cancer risk assessment, early diagnosis, and prevention. His active research includes basic etiologic studies of genetic susceptibility to EA and its precursor, Barrett’s esophagus (BE); applied biomarker discovery studies of circulating nucleic acids and metabolites linked to high-risk BE and early-stage EA; and integrative risk modeling studies aimed at combining genetic and non-genetic factors into robust predictors of absolute cancer risk. The long-term translational goal of this work is to synthesize improved clinical tools for enabling targeted prevention or timely interception of EA among at-risk individuals.

Contact Information:

Phone: 716-845-4754
Fax: 716-845-8487
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Carlton House A369
Buffalo, NY 14263


Full Publications list on PubMed
  • Dai JY, Wang X, Buas MF, Zhang C, Ma J, Wei B, Li Y, Zhao B, Hyun TS, Chen X, Loeb KR, Odze R, Yao L, Sun X, Self S, Vaughan TL, Guo Y. Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations. Commun Biol. 2018 Oct 24;1:174. doi: 10.1038/s42003-018-0182-8. PMID: 30374464; PMCID: PMC6200836.
  • Buas MF, Gu H, Djukovic D, Zhu J, Onstad L, Reid BJ, Raftery D, Vaughan TL. Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics. 2017 Mar;13(3):23. doi: 10.1007/s11306-016-1154-y. Epub 2017 Jan 20. PMID: 28190989; PMCID: PMC5295138.
  • Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, Wu AH, Ye W, Bird NC, Bernstein L, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA, Iyer PG, Reid BJ, Hardie LJ, Lagergren J, Shaheen NJ, Corley DA, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) consortium, Whiteman DC, Vaughan TL, Thrift AP. Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. Gastroenterology. 2018 Apr;154(5):1273-1281.e3. doi: 10.1053/j.gastro.2017.12.003. Epub 2017 Dec 13. PMID: 29247777; PMCID: PMC5880715.
  • Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, Gharahkhani P, Palles C, Lagergren J, Fitzgerald RC, Ye W, Caldas C, Bird NC, Shaheen NJ, Bernstein L, Gammon MD, Wu AH, Hardie LJ, Pharoah PD, Liu G, Iyer P, Corley DA, Risch HA, Chow WH, Prenen H, Chegwidden L, Love S, Attwood S, Moayyedi P, MacDonald D, Harrison R, Watson P, Barr H, deCaestecker J, Tomlinson I, Jankowski J, Whiteman DC, MacGregor S, Vaughan TL, Madeleine MM. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2017 Oct;66(10):1739-1747. doi: 10.1136/gutjnl-2016-311622. Epub 2016 Aug 2. PMID: 27486097; PMCID: PMC5296402.
  • Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON); Esophageal Adenocarcinoma GenEtics Consortium (EAGLE); Wellcome Trust Case Control Consortium 2 (WTCCC2), Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RGP, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J. Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncol. 2016 Oct;17(10):1363-1373. doi: 10.1016/S1470-2045(16)30240-6. Epub 2016 Aug 12. PMID: 27527254; PMCID: PMC5052458.
  • Dai JY, Tapsoba Jde D, Buas MF; BEACON Consortium, Risch HA, Vaughan TL. Constrained Score Statistics Identify Genetic Variants Interacting with Multiple Risk Factors in Barrett's Esophagus. Am J Hum Genet. 2016 Aug 4;99(2):352-65. doi: 10.1016/j.ajhg.2016.06.018. PMID: 27486777; PMCID: PMC4974090.
  • Buas MF, Gu H, Djukovic D, Zhu J, Drescher CW, Urban N, Raftery D, Li CI. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. Gynecol Oncol. 2016 Jan;140(1):138-44. doi: 10.1016/j.ygyno.2015.10.021. Epub 2015 Oct 30. PMID: 26521694; PMCID: PMC5310763.
  • Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, Galipeau PC, Shaheen NJ, Hardie LJ, Romero Y, Bernstein L, Gammon MD, Casson AG, Bird NC, Risch HA, Ye W, Liu G, Corley DA, Blount PL, Fitzgerald RC, Whiteman DC, Wu AH, Reid BJ, Vaughan TL. Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis. 2014 Dec;35(12):2740-7. doi: 10.1093/carcin/bgu207. Epub 2014 Oct 3. PMID: 25280564; PMCID: PMC4247522.

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment